EnPlusOne Biosciences

Executive Summary

EnPlusOne Biosciences, based in Cambridge, MA, is pioneering an enzymatic RNA synthesis platform to overcome critical limitations in RNA therapeutics manufacturing. Current chemical synthesis methods access only ~20 of the >200 natural RNA modifications, constraining the design and efficacy of RNA drugs. EnPlusOne's flexible enzymatic platform enables unrestricted scale and access to the full repertoire of natural modifications, potentially unlocking next-generation RNA therapeutics with improved stability, reduced immunogenicity, and enhanced delivery. Founded in 2021, the company addresses urgent industry need as RNA therapeutics accelerate faster than manufacturing capabilities. By enabling a broader chemical space for RNA drug development, EnPlusOne positions itself as a key enabler for the RNA therapeutics ecosystem, targeting applications in vaccines, gene editing, and protein replacement. While still in early stages, its technology could transform RNA manufacturing, offering a scalable, cost-effective alternative to chemical synthesis.

Upcoming Catalysts (preview)

• Q3 2026Publication or presentation of enzymatic synthesis of diverse RNA modifications70% success
• Q4 2026Series A funding round or strategic partnership60% success
• Q2 2027Collaboration with a major RNA therapeutics company50% success